Latest tweet from our researchers:

Kong W, He L, Zhu J, Brück O, Porkka K, Heckman CA, Zhu S, Aittokallio T (2022)
An immunity and pyroptosis gene-pair signature predicts overall survival in acute myeloid leukemia
Leukemia (in press)
DOI 10.1038/s41375-022-01662-6, PubMed 35945345

Berg J, Halvorsen AR, Bengtson MB, Lindberg M, Halvorsen B, Aukrust P, Helland Å, Ueland T (2022)
Circulating T Cell Activation and Exhaustion Markers Are Associated With Radiation Pneumonitis and Poor Survival in Non-Small-Cell Lung Cancer
Front Immunol, 13, 875152
DOI 10.3389/fimmu.2022.875152, PubMed 35911763

Skanland SS, Brown JR (2022)
PI3K inhibitors in chronic lymphocytic leukemia: where do we go from here?
Haematologica (in press)
DOI 10.3324/haematol.2022.281266, PubMed 35899388

Staaf J, Häkkinen J, Hegardt C, Saal LH, Kimbung S, Hedenfalk I, Lien T, Sørlie T, Naume B, Russnes H, Marcone R, Ayyanan A, Brisken C, Malterling RR, Asking B, Olofsson H, Lindman H, Bendahl PO, Ehinger A, Larsson C, Loman N, Rydén L, Malmberg M, Borg Å, Vallon-Christersson J (2022)
RNA sequencing-based single sample predictors of molecular subtype and risk of recurrence for clinical assessment of early-stage breast cancer
NPJ Breast Cancer, 8 (1), 94
DOI 10.1038/s41523-022-00465-3, PubMed 35974007

Denisova OV, Merisaari J, Kaur A, Yetukuri L, Jumppanen M, von Schantz-Fant C, Ohlmeyer M, Wennerberg K, Aittokallio T, Taipale M, Westermarck J (2022)
Development of actionable targets of multi-kinase inhibitors (AToMI) screening platform to dissect kinase targets of staurosporines in glioblastoma cells
Sci Rep, 12 (1), 13796
DOI 10.1038/s41598-022-18118-7, PubMed 35963891

Venizelos A, Engebrethsen C, Deng W, Geisler J, Geisler S, Iversen GT, Aas T, Aase HS, Seyedzadeh M, Steinskog ES, Myklebost O, Nakken S, Vodak D, Hovig E, Meza-Zepeda LA, Lønning PE, Knappskog S, Eikesdal HP (2022)
Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapy
Genome Med, 14 (1), 86
DOI 10.1186/s13073-022-01090-2, PubMed 35948919